ICD-10-CM 2027 diagnosis code
D09.8Carcinoma in situ of other specified sites
D09.8 is a valid, billable ICD-10-CM code for carcinoma in situ of other specified sites. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.
Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS, effective October 1, 2026. Updated September 29, 2026. About our data
About D09.8
D09.8 is the ICD-10-CM diagnosis code for carcinoma in situ of other specified sites. It belongs to category D09 (carcinoma in situ of other and unspecified sites), block D00-D09 (in situ neoplasms) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
Within D09, choose D09.8 (situ of other specified sites) only when documentation doesn't support a more specific option: situ of bladder (D09.0), situ of other and unspecified urinary organs (D09.1), situ of eye (D09.2), situ of thyroid and other endocrine glands (D09.3) and situ, unspecified (D09.9).
It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.
In MS-DRG v44.0, it is part of the grouping logic for DRG 826 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC, relative weight 4.7581), DRG 827 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC, relative weight 2.3896), DRG 828 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC, relative weight 1.6955), DRG 829 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC, relative weight 3.1281), DRG 830 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC, relative weight 1.4859), DRG 843 (Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC, relative weight 1.9453) and 2 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.
Before ICD-10, this condition was coded in ICD-9-CM as 234.8 (carcinoma in situ of other specified sites).
Notes that apply from higher levels
Instructions written at a parent level also apply to D09.8.
› From D09 Carcinoma in situ of other and unspecified sites
- melanoma in situ (D03.-)
Broader instructions also apply from D00-D09 In situ neoplasms and Chapter 2: Neoplasms.
Table of Drugs & Neoplasms entries
- Neoplasm, neoplastic › abdomen, abdominal — Ca in situ
- Neoplasm, neoplastic › abdomen, abdominal › cavity — Ca in situ
- Neoplasm, neoplastic › abdomen, abdominal › organ — Ca in situ
- Neoplasm, neoplastic › abdomen, abdominal › viscera — Ca in situ
- Neoplasm, neoplastic › axilla, axillary — Ca in situ
- Neoplasm, neoplastic › cervical region — Ca in situ
- Neoplasm, neoplastic › cheek — Ca in situ
- Neoplasm, neoplastic › chest (wall) NEC — Ca in situ
- Neoplasm, neoplastic › extrarectal — Ca in situ
- Neoplasm, neoplastic › fossa (of) › ischiorectal — Ca in situ
- Neoplasm, neoplastic › intra-abdominal — Ca in situ
- Neoplasm, neoplastic › intrathoracic (cavity) (organs) — Ca in situ
- Neoplasm, neoplastic › intrathoracic (cavity) (organs) › specified NEC — Ca in situ
- Neoplasm, neoplastic › ischiorectal (fossa) — Ca in situ
- Neoplasm, neoplastic › jaw — Ca in situ
- Neoplasm, neoplastic › neck NEC — Ca in situ
- Neoplasm, neoplastic › nose, nasal — Ca in situ
- Neoplasm, neoplastic › parasagittal (region) — Ca in situ
- Neoplasm, neoplastic › pelvis, pelvic — Ca in situ
- Neoplasm, neoplastic › pelvis, pelvic › floor — Ca in situ
- Neoplasm, neoplastic › pelvis, pelvic › viscera — Ca in situ
- Neoplasm, neoplastic › pelvis, pelvic › wall — Ca in situ
- Neoplasm, neoplastic › pelvo-abdominal — Ca in situ
- Neoplasm, neoplastic › perineum — Ca in situ
- Neoplasm, neoplastic › peritonsillar (tissue) — Ca in situ
- Neoplasm, neoplastic › rectovaginal septum or wall — Ca in situ
- Neoplasm, neoplastic › rectovesical septum — Ca in situ
- Neoplasm, neoplastic › retro-orbital — Ca in situ
- Neoplasm, neoplastic › retrovesical (septum) — Ca in situ
- Neoplasm, neoplastic › sacrococcyx, sacrococcygeal › region — Ca in situ
Codes whose notes reference D09.8
- D02.3Excludes1
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
- 826Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCCRW 4.7581
- 827Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CCRW 2.3896
- 828Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCCRW 1.6955
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
- 843Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCCRW 1.9453
- 844Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with CCRW 1.2551
- 845Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses without CC/MCCRW 0.8447
ICD-9-CM equivalent
Converter →- 234.8Carcinoma in situ of other specified sitesapproximate
From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
- No changes since FY2016.
Common questions about D09.8
Is D09.8 billable?
- Yes. D09.8 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
Can D09.8 be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict D09.8 as a principal diagnosis.
Is D09.8 a CC or MCC?
- No. D09.8 is neither a CC nor an MCC under MS-DRG v44.0.
What DRG does D09.8 group to?
- D09.8 is used in the MS-DRG v44.0 logic for MS-DRG 826 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC), MS-DRG 827 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC), MS-DRG 828 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC), MS-DRG 829 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC), MS-DRG 830 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC), MS-DRG 843 (Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC) and 2 more. Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.
What is the ICD-9 code for D09.8?
- The CMS General Equivalence Mappings map D09.8 to ICD-9-CM 234.8.